LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment [Yahoo! Finance]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Yahoo! Finance
LB Pharma's lead asset, LB-102, is a patent protected blood-brain barrier-optimized analog of amisulpride, a well-established antipsychotic widely used in Europe LB-102 is designed to address both the positive and negative symptoms of schizophrenia LB Pharma expects to announce top-line data from its LB-102 Phase 2 trial in the first quarter of 2025 LB Pharma is backed by institutional investors Deep Track Capital, TCGx Crossover, Vida Ventures, and Pontifax NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company advancing treatments for schizophrenia, today announced the appointment of Heather Turner as Chief Executive Officer and member of the Board of Directors. Ms. Turner succeeds Zachary Prensky, co-founder of LB Pharma, who will serve as an advisor to the CEO through the end of 2024. Mr. Prensky will remain on the Board and contribute as a consultant thereafter. Treating both the positive symptoms of schizophrenia
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.MarketBeat
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024GlobeNewswire
- Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingGlobeNewswire
LYEL
Sec Filings
- 11/12/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- LYEL's page on the SEC website